Monograph
C01CE01 - Amrinone |
Propably not porphyrinogenic |
PNP |
Rationale
Probably non-CYP dependent metabolism. No data pointing to CYP-interaction.
Chemical description
Bipyridin.
Therapeutic characteristics
Non-catecholamine, non-glucoside inotropic drug used in acute heart failure.
Metabolism and pharmacokinetics
Amrinone (synonym inamrinone) is partially metabolised in the liver and excreted in the urine as unchanged drug and metabolites (N-glycolyl, N-acetate, O-glucuronide, N-glucuronide); up to about 40% is excreted as unchanged drug after intravenous administration. The major metabolic pathways of inamrinone are all conjugative, which involve glucuronidation, glutathione addition, and acetylation. If at all, the CYP450-system probably does not play a significant role.
Preclinical data
None
Personal communication
None
Published experience
None
Similar drugs
Tradenames and packages
© NAPOS 2024